摘要
AIM: To report our experience with empiric antimicrobial monotherapy (piperacillin/tazobactam, of which no data are available in such specific circumstances) in microbiologically-documented infections in patients with benign and malignant conditions of the biliary tract.METHODS: Twenty-three patients, 10 with benign and 13 with malignant conditions affecting the biliary tree and microbiologically-documented infections were recruited and the efficacy of empirical antibiotic therapy was assessed.RESULTS: The two groups featured similar demographic and clinical data. Overall, the infective episodes were most due to Gram negative agents, more than 60% of such episodes (mostly in malignant conditions) were preceded by invasive instrumental maneuvers. Empirical antibiotic therapy with a single agent (piperacillin/tazobactam) was effective in more than 80% of cases. No deaths were reported following infections. CONCLUSION: An empiric therapeutic approach with piperacillin/tazobactam is highly effective in biliary tract infections due to benign or malignant conditions.
AIM:To report our experience with empiric antimicrobial monotherapy(piperacillin/tazobactam,of which no data are available in such specific circumstances)in microbiologically-documented infections in patients with benign and malignant conditions of the biliary tract. METHODS:Twenty-three patients,10 with benign and 13 with malignant conditions affecting the biliary tree and microbiologically-documented infections were recruited and the efficacy of empirical antibiotic therapy was assessed. RESULTS:The two groups featured similar demographic and clinical data.Overall,the infective episodes were most due to Gram negative agents,more than 60% of such episodes(mostly in malignant conditions)were preceded by invasive instrumental maneuvers.Empirical antibiotic therapy with a single agent(piperacillin/tazobactam)was effective in more than 80% of cases.No deaths were reported following infections. CONCLUSION:An empiric therapeutic approach with piperacillin/tazobactam is highly effective in biliary tract infections due to benign or malignant conditions.
